(Q44900430)

7 December 2017

title

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden (English)

1 reference

7 December 2017

0 references

1 reference

1 reference

7 December 2017

A M Vannucchi

1 reference

7 December 2017

E Antonioli

1 reference

7 December 2017

G Longo

1 reference

7 December 2017

A Pancrazzi

1 reference

7 December 2017

V Ponziani

1 reference

7 December 2017

C Bogani

1 reference

7 December 2017

P R Ferrini

1 reference

7 December 2017

A Rambaldi

1 reference

7 December 2017

V Guerini

1 reference

7 December 2017

A Bosi

1 reference

7 December 2017

T Barbui

1 reference

7 December 2017

MPD Research Consortium

1 reference

7 December 2017

publication date

12 July 2007

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

page(s)

1952-1959

1 reference

The myeloproliferative disorders

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

On the molecular origins of the chronic myeloproliferative disorders: it all makes sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Mutation screening for JAK2V617F: when to order the test and how to interpret the results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Evidence-based management of polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

How I treat patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

7 January 2021

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

7 January 2021

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

7 January 2021

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

7 January 2021

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

7 January 2021

Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

7 January 2021

Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404854

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404854

1 reference

Dimensions Publication ID

7 December 2017

1040238589

0 references

1 reference